Diaceutics

Analyzing utilization data, Diaceutics found that issues around 13 genetic tests prevent around 78,000 patients from getting personalized, targeted treatments each year.

Diaceutics will use the data to help its pharmaceutical industry clients speed their rollouts of new cancer drugs.

Stakeholder input on FDA's draft Rx/Dx codevelopment guidance signals that precision medicine is actually developed differently than the agency wants it to be.

There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.

This type of test is intended to help guide personalized treatment, but will doctors order it and payors reimburse it if it's not required for the safe and effective use of a drug?

Under the partnership, the companies will help drugmakers efficiently implement complementary and companion tests through lab networks.

Originally published Nov. 10.
NEW YORK (GenomeWeb) – Consulting firm Diaceutics has released a report that shows pharmaceutical companies' readiness to develop and deliver personalized medicines has improved since 2010, at least according to the numbers.

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

Peter Kim, former Merck Research Laboratories president, will return to his alma mater Stanford University as a professor of biochemistry at the School of Medicine.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.